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A sequence of interconnected events known as the metastatic cascade promotes tumor
progression by regulating cellular and molecular interactions between tumor, stromal,
endothelial, and immune cells both locally and systemically. Recently, a new concept has
emerged to better describe this process by defining four attributes that metastatic cells
should undergo. Every individual hallmark represents a unique trait of a metastatic cell
that impacts directly in the outcome of the metastasis process. These critical features,
known as the hallmarks of metastasis, include motility and invasion, modulation of the
microenvironment, cell plasticity and colonization. They are hierarchically regulated at dif-
ferent levels by several factors, including galectins, a highly conserved family of β-galac-
toside-binding proteins abundantly expressed in tumor microenvironments and sites of
metastasis. In this review, we discuss the role of galectins in modulating each hallmark of
metastasis, highlighting novel therapeutic opportunities for treating the metastatic
disease.
Introduction
Along with the improvement of surgical techniques and the implementation of neoadjuvant therapies,
the mortality rate of many primary tumors has dramatically decreased [1], being metastatic spread the
most lethal attribute of neoplastic cells [2]. To describe the process that epithelial carcinomas should
undergo to achieve a higher grade of malignancy, a model of interconnected events known as ‘the
Hallmarks of Metastasis’ has been proposed. This new concept, based on the Hallmarks of Cancer
described by Hanahan and Weinberg [1,3], introduced four well-defined attributes shared by all meta-
static cells [2]. Every hallmark represents a trait of the metastatic cell which directly impacts in the
success of the ‘metastatic cascade’. To proceed with the metastatic process, tumor cells must acquire
these specific hallmarks, namely: (a) motility and invasion which enables tumor cells to leave primary
sites and spread towards the pre-metastatic niche; (b) modulation of the microenvironment, which
allows interactions with the stroma to promote a tissue architecture endowed with the pro-metastatic
configuration; (c) plasticity to survive in the hostile conditions of the new environment; and (d) colon-
ization to usurp the pre-metastatic niche and to establish a supportive neighborhood for seeding and
outgrowth [2]. This categorization, based on distinctive and complementary capabilities of the meta-
static cell, intends to associate each hallmark with genotypic and phenotypic attributes that are crucial
for the metastatic outgrowth. A better understanding of these features would lead to the identification
of novel biomarkers, to improve early diagnosis and to boost therapeutic strategies.
In the past decade, galectins, a family of highly conserved β-galactoside-binding proteins, emerged
as key regulators of tumor progression, not only by influencing primary tumor growth but also by
shaping the metastatic process [4]. Galectins are glycan-binding proteins that control a wide range of
biological processes including cell invasion, migration, immune evasion, and angiogenesis. At the
molecular level, galectins fine-tune signaling of different cell surface receptors by establishing multiva-
lent interactions with specific glycosylated ligands [5,6]. Different tumors exhibit differential galectin
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landscapes that hierarchically serve as ‘on–off’ switchers that control different Hallmarks of Cancer including
invasion and metastasis. Blockade of galectin–glycan interactions thus represents a novel strategy to halt tumor
progression [7]. In this review, we will discuss the involvement of galectins in different hallmarks of metastasis
and the molecular pathways that govern their function in the context of tumor progression.
The hallmarks of metastasis
The metastatic process consists of sequential events that must be accomplished for successful secondary organ
colonization. This multistage process, known as the metastatic cascade, is endowed with defined features char-
acterized as the ‘Hallmarks of Metastasis’ including the acquisition of motility and migration, dynamic modifi-
cation of the metastatic milieu and the plasticity to overcome hostile environments in order to colonize the
pre-metastatic niche in target organs (Figure 1). As a first step, tumor cells must leave the primary tumor site
and invade local tissue surroundings by degrading the basal membrane (invasion); then they foster the forma-
tion of new blood vessels (neo-angiogenesis), leak into the bloodstream (intravasation) and travel in the circula-
tion (dissemination) until anchoring in the distant stroma (extravasation), where it finally settles in the target
organ (colonization) [8]. Cells that have already left the primary tumor, either at an early or late stage of the
disease, are known as disseminated tumor cells (DTC) [9]. DTCs experience a reprogrammed phenotype which
endows these cells with the capacity to circumvent unfavorable events and to adapt to environmental changes [10].
Once the secondary organ is reached, DTC can either proliferate and give rise to macrometastasis or remain
dormant for years or decades [11,12]. This hibernation state is reversible, and many factors have been proposed
to awake the dormant cell. This ‘awakening’ process is in general triggered by microenvironmental stimuli but
could also be driven by internal signals and activation of certain transcription factors [13].
Galectins: key players in the control of the metastatic cascade
Galectins are a family of glycan-binding proteins that recognize N-acetyl-lactosamine (Galβ1-4NAcGlc;
LacNAc) residues in complex branched N-glycans and extended core 2-O-glycans. Galectins display both, intra-
cellular and extracellular functions that contribute to tumor progression. Members of this family can be classi-
fied, based on their architecture, in three major subgroups called: (a): ‘proto-type’ galectins (Gal1, Gal2, Gal5,
Gal7, Gal10, Gal11, Gal13, Gal14, and Gal15) consisting of subunits with a single carbohydrate-recognition
domain (CRD) and the ability to self-associate as dimers via non-covalent bonds; ‘tandem-repeat’ galectins
(Gal4, Gal6, Gal8, Gal9, and Gal12) sharing two homologous CRDs connected by a linker peptide and the
‘chimera-type’ galectins, being Gal3 the unique member of this group, which may exist as monomer, but can
Figure 1. The Hallmarks of Metastasis.
(a) Welch and Hurst proposed a subcategorization of the Hallmarks of Cancer named as the Hallmarks of metastasis to
describe the four traits that successful metastatic tumor cells share [2]. (b) Every feature has a direct impact on the progression
of the metastatic cascade leading to colonization and formation of macrometastasis. Created with BioRender.com.
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also dimerize or multimerize (particularly in pentamers). The N-terminal domain as well as the beginning of
the a C-terminal carbohydrate-binding domain (CBD) of Gal3, are involved in dimerization and multimeriza-
tion processes, making higher-order complexes in the presence of higher-order sugars [14–17] (Figure 2).
Through binding to different glycosylated receptors (glycoproteins or glycolipids) on the surface of different
cell types, galectins can trigger activation of signaling pathways that co-operate to reprogram several key pro-
cesses including antitumor immunity, angiogenesis, genomic instability, and neoplastic transformation [4].
Accumulating evidence indicates that galectin expression is altered in tumors and in the tumor-associated
stroma, playing active roles during tumor progression. Recently, we reviewed mechanisms, signaling, and path-
ways through which galectins may influence different ‘Hallmarks of Cancer’ [7]. In this review, we will dissect
the impact of galectins in the so-called ‘Hallmarks of Metastasis’ focusing on how these endogenous lectins
influence different events of the tumor metastasis cascade.
Figure 2. Galectins: structural and biochemical features.
(a) Structural representation of different galectin family members. Galectins are subdivided into three groups: (i) ‘Prototype’
(Gal1, Gal2, Gal5, Gal7, Gal10, Gal11, Gal13, Gal14, and Gal15) with one CRD and ability to form homodimers; (ii)
‘Tandem-repeat’ galectins (Gal4, Gal6, Gal8, Gal9, and Gal12), with two different CRDs connected by a linker peptide; and (iii)
the ‘Chimera type’ galectin, being Gal3 the only member of this family, which can exist as monomer but can also dimerize or
multimerize (particularly in pentamers). (b) Scheme of distinct types of lattices, that could be potentially assembled through
interactions between multivalent galectins and glycans. Bivalent, trivalent and tetravalent ligands associated with multivalent
galectins can give rise to the formation of distinct three-dimensional configurations and arrays that trigger or re-wire signaling
pathways. Created with BioRender.com.
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Motility and invasion
Extracellular and intracellular signals govern tumor cell fate promoting the invasion of the tumor surrounding
area as a first hallmark of the metastatic process. Tumor cells may co-opt galectin-driven pathways that are
used during normal development, for invasion and dissemination. For example, normal mammary epithelial
cells proliferate and migrate, within their surrounding stroma, during the branching stage of mammary gland
morphogenesis. This process may be controlled by the dynamics of Gal1 subcellular localization [18].
Interestingly, at the invading edge of the normal mouse mammary gland, Gal1 was found to be abundant in
the nucleus of proliferating epithelial cells of the end buds, where it is involved in pre-mRNA splicing and
coexists in a complex with Gemin-4 [18]. Thus, in spite of its nuclear localization and function in physiologic
settings, this lectin impacts significantly on the migration and invasion of the transformed mammary cell.
Accordingly, Gal1 is forced to translocate to the nucleus of malignant breast cancer cells due to an increased
α2,6-sialylation (α2,6 SA) of membrane glycoconjugates, that are restrictive for its binding. Thus, Gal1 serves
as a major driving force for tumor cell invasion during breast tumor progression [18].
Reinforcing the idea that galectins play a role in normal invasive programs, Gal1 and Gal3 have been
described as active members of the human trophoblast invasion machinery. Blocking both galectins in HTR-8/
SVneo cells derived from human placenta, led to a significant reduction in cell migration and invasion [19,20].
Moreover, Gal7 has also been proposed as a key regulator of epithelial cell homeostasis since it modulates cell
growth, differentiation, and apoptosis. Likewise, in epithelial wound healing, a non-transformed scenario of cell
invasion, Gal7 controls keratinocytes migration in mouse corneas and epidermis [21,22].
As generally occurs in physiological events involving cell migration and invasion, most tumor cells invade
surrounding tissues either as clusters in a process named collective migration or as single cells depending on
the microenvironmental conditions. Collective migration relies in the interactions of tumor cells with their
neighborhood, where cell–cell junctions as desmosomal proteins, gap junctions, and tight junctions are key
players, forming a cohesive group of cells that proceed with migration and invasion by degrading extracellular
matrix (ECM) components [23]. In this regard, cell–cell junctions are modulated by several signaling pathways
such as phosphatidylinositol 3-kinase (PI3K)/AKT, extracellular signal-regulated kinase (ERK), c-Jun
N-terminal kinase ( JNK), focal adhesion kinase (FAK), and Rho GTPases [23] that sense the environmental
conditions and modulate homotypic and heterotypic cell interactions. On the contrary, single cells can invade
the surrounding area following two distinct mechanisms, a mesenchymal invasion or a Rho/ROCK-dependent
ameboid process. In this regard, Gal1 can favor both types of migration by favoring mesenchymal transform-
ation and increasing the number and length of filopodia on tumor cells via the Rho-dependent signaling
pathway [24].
Interestingly, DTC have the ability of modulating the microenvironment and at the same time, are endowed
with remarkable plasticity mainly through a mesenchymal and/or stem cell phenotype. The strong plasticity of
a DTC has direct impact on its motility and invasion capacities, suggesting that the four Hallmarks of
Metastasis are deeply interconnected, and all are functionally related. Here, we will dissect the role of galectins
in regulating motility and invasion of tumor cells by remodeling the extracellular matrix, orchestrating the
stromal cells cross-talk, and favoring development of pro-metastatic niches.
Modulation of the microenvironment
Extracellular matrix remodeling
Several studies showed that galectins can affect the cross-talk between tumor cells and the ECM [4]. Galectins
bind to a wide array of glycoproteins and glycolipids on the cell surface and the ECM, delivering signals and
mediating cell–cell and cell–ECM adhesion. Accordingly, galectins can interact with both N- and O-glycans
present on glycoproteins of the ECM such as fibronectin, elastin, hensin, and laminin [4]. In particular, Gal1
promotes attachment of melanoma cell lines (A375 and A2058) and ovarian cell lines (AZ224, SK-OV-3,
AZ382 OVCAR-3, and AZ224) to laminin-1 and fibronectin in a dose-dependent manner [25,26]. In addition,
Gal3 interacts with both soluble and insoluble elastin, regulating the adhesive interactions between breast car-
cinoma cells (MDA-MB-231 and BT-474) with the ECM [27]. Moreover, in melanoma cells, Gal3 oligomers
controlled the interactions of elastin and αvβ3 integrin modulating their invasive capacity [28] (Figure 3).
Interestingly, Gal1 induces up-regulation of matrix metalloproteinases MMP-2 and MMP-9 and stimulates
actin cytoskeleton reorganization in oral cancer and in lung adenocarcinoma (Figure 3). Also, Gal7, another
prototype galectin that is highly expressed in oral squamous cell carcinoma (OSCC), promoted invasiveness
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through ERK and JNK signaling and facilitated migration via the expression of MMP-2 and MMP-9 [29]
(Figure 3). Similarly, Gal3 increased the activities of the same metalloproteinases, promoting cell invasion in
pancreatic and tongue cancer cells through PI3K/AKT and β-catenin signaling pathways [30–32] (Figure 3).
Furthermore, Gal3 binding to complex N-glycans on mammary epithelial tumor cells, modulated fibronectin-
dependent matrix remodeling, promoted α5β1 integrin recruitment and FAK activation, thus increasing tumor
cell motility [33]. Therefore, different members of the galectin family foster tumor cell adhesion and migration
not only by stimulating interactions with glycoconjugates present in the ECM, but also by promoting remodel-
ing of its composition and structure.
Figure 3. Galectins control tumor cell migration, invasion, and intravasation processes.
(a) Tumor cells may disrupt the basement membrane to invade the stroma. Gal1, 3 and 7 enhance metalloproteinases (MMP-2
and MMP-9) secretion and integrin/collagen disruption. (b) Gal1, Gal3 and Gal9 influence cell plasticity promoting
epithelial-to-mesenchymal transition (EMT) and stemness (Wnt/β-catenin) having a direct impact on motility, migration, and
invasion. (c) Galectins promote neoangiogenesis through binding to VEGFR2 (Gal1), by stimulating the proangiogenic capacity
of tumor-associated macrophages (TAMs) or through binding to αvβ3 integrin (Gal3), through association with ALCAM/CD166
(Gal8), or by recognizing 30 fucosylated residues (Gal12). (d) Gal3 interacts with Thomsen–Friedenreic (TF) antigen enhancing
adhesion and intravasation and Gal9 promotes ECM adhesion. (e) Cells can migrate either as single cells or in clusters.
Galectins promote homotypic and heterotypic aggregation of tumor cells. Gal1, Gal3, and Gal9 enhance the aggregation of
platelets with tumor cells aiding survival in the circulation. Interaction between Gal3 and MUC1 favor emboli formation and
heterotypic aggregation. Created with BioRender.com.
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Tumor–stroma cross-talk
Mammary ductal carcinoma in situ (DCIS) is a proliferation of neoplastic luminal cells that are confined to the
duct-lobular system of the breast. If DCIS progresses to invasive ductal carcinoma (IDC), tumor cells infiltrate
the parenchyma after basement membrane disruption [34]. Consistent with the effect of immune regulatory
mediators in shaping tumor evolution toward an invasive phenotype, a switch toward a tolerogenic immune
environment during the transition from DCIS to IDC was recently demonstrated. At early stages of the dissem-
ination process, dysregulation in the balance of pro- and anti-metastatic signals dictates the outcome the tumor
progression. Accordingly, the galectin gene expression signature of the breast tumor stroma was found to be
associated with positive or negative clinical outcomes. In this context, triple-negative (TN) and HER2+ breast
cancer patients showed a stromal signature expression characterized by the prevalence of Gal1, Gal3, and Gal9
that was associated with poor prognosis [35]. Within the TME, cancer-associated fibroblasts (CAFs) play a
major role during tumor progression [36], through the secretion of growth factors and cytokines that activate
receptors present on tumor cells. Several studies revealed that Gal1 released by human pancreatic stellate cells
(which function as CAF in the pancreatic TME) induces progression of preneoplastic pancreatic lesions and
promotes the release of stromal cell-derived factor-1 (SDF-1) which increases migration and invasion of pancre-
atic cancer cells [37,38]. Importantly, in a mouse model of pancreatic ductal adenocarcinoma (PDAC), tumoral
Gal1 induces activation of CAF, thus contributing to TME remodeling [39]. In line with these findings, in
human cells, knocking down Gal1 inhibited CAF-induced tumor cell migration and invasion by reducing the
production of monocyte chemoattractant protein-1 (MCP-1/CCL2) [40]. Furthermore, in gastric carcinoma
cells, CAF-derived Gal1-induced epithelial-mesenchymal transition (EMT) via hedgehog pathway activation [41].
Thus, galectins govern tumor–stroma interactions through mechanisms involving immune and inflammatory
components, further contributing to immune escape (Figure 4).
Figure 4. Galectins reprogram antitumor immune response by shaping myeloid and lymphoid cell compartments.
Effects of Gal1, Gal3, and Gal9 on different innate and adaptive immune cell types and the consequence of these interactions
in immune evasion mechanisms and metastatic events. Created with BioRender.com.
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Innate antitumor immunity
Galectins have the ability to shape the innate immune compartment, thus influencing early antitumor immun-
ity and promoting a predominant immunosuppressive or tolerogenic profile (Figure 4). In a B16 melanoma
model, Gal1 fostered the differentiation of tolerogenic dendritic cells (DCs) [42] and inhibited transendothelial
migration of inflammatory DCs [43]. This lectin facilitated the recruitment of monocytic and granulocytic
myeloid-derived suppressor cells (MDSCs) and TAMs (CD11bhighF4/80+) into the TEM in a mouse glioma
model (GL261 cell line) [44]. In addition, Gal1 polarized macrophages and microglia into an M2 anti-
inflammatory profile [45,46]. In this regard, Gal1 expression has been considered a mechanism of evasion of
innate immunity in another glioma model (GL26). Gal1 knockdown in GL26 cells resulted in heightened
inflammatory responses leading to rapid recruitment of Gr-1(+)/CD11b(+) myeloid cells and NK cells into the
brain TME, thus influencing tumor immunoediting [47]. Additionally, tumor-derived Gal3 impacts the cyto-
toxic potential of NK cell activating-receptors such as NKG2D and NKp30. In particular, in bladder tumor
cells, Gal3 binding to core 2 O-glycans present on MHC class I-related chain A molecule (MICA), dismantled
the interactions between this ligand and NKG2D in NK cells, thus blunting NK-mediated killing potential [48].
Moreover, in human cervical cancer and breast cancer cell lines, Gal3 acts as a soluble inhibitory ligand for the
NKp30 receptor [49]. In a mouse tumor model of melanoma, Gal3 also enhanced polarization of macrophages
toward a M2 phenotype [50], thus tilting the balance toward an immunosuppressive antitumor response.
Recently, it was shown that Gal9 binds to the mannose receptor CD206 present on M2 macrophages and sti-
mulates the release of fibroblast growth factor (FGF)-2 and MCP-1, thus supporting tumor growth in metastatic
melanoma patients [51]. Of note, Gal9 also favors expansion of granulocytic (CD11b + Ly6G+) MDSCs pro-
moting tumor growth in EL4 thymoma cells and 4T1 mouse breast cancer cells [52]. On the other hand, in
colon cancer, Gal9 modulates NK cells by promoting F-actin polarization of NK cells via Rho/ROCK1 activa-
tion [53]. Thus, galectins may serve as critical mediators of tumor-promoting inflammation and regulators of
innate immunity acting at early stages of tumor development and preventing activation of antitumor adaptive
responses.
Adaptive antitumor immunity
Galectins may influence the progression of the metastatic cascade by blunting the antitumor adaptive responses.
In particular, Gal1 expression thwarts antitumor immunity through several mechanisms, including the promo-
tion of T-cell apoptosis, suppression of T-cell activation, induction of anti-inflammatory Th2 responses and
expansion of regulatory T cells (Tregs) [54–56]. Mechanistically, Gal1 induces selective death of Th1 and Th17
cells due to differential glycosylation of these cells as evidenced by low frequency of α2,6-linked sialic acid
(α2,6SA) and higher elongation of core 2 O-glycans. On the contrary, Th2 cells are protected from
Gal1-induced cell death through α2,6 sialylation of cell surface glycoproteins. As a result, Th2 cells are
protected from Gal1-induced cell death, leading to a relative increase in the frequency of this T-cell
subpopulation [57]. Taken together, these properties license Gal1 as part of an immune evasive program
confirmed in several tumor types including melanoma, classical Hodgkin lymphoma, HNSC, neuroblastoma,
glioblastoma as well as ovary, pancreatic, prostate and breast adenocarcinoma, among others. In addition, Gal1
released by human PSCs promotes a Th2-skewed cytokine profile along with activation of caspases-9 and 3 and
triggering of the mitochondrial apoptotic pathway [58]. Deletion of Gal1 in a Kras-driven model of PDAC
(Ela-KrasG12Vp53−/−) promoted mice survival and increased T-cell infiltration in established tumors [59]. This
profile was also evident in classical Hodgkin lymphoma which expressed Gal1 via an enhancer of the activating
protein 1 (AP1) transcription factor [60].
T-cell exclusion thwarts antitumor responses by limiting access of T cells to tumor antigens. In HNSC, Gal1
expression prevented T-cell infiltration into the tumor bed and increased resistance to anti-PD-1 immune
checkpoint blockers by inducing Gal9 expression in endothelial cells (ECs) [61]. In breast cancer, invasion of
tumor-draining lymph nodes (TDLN) by metastatic cells correlated with poor prognosis and was associated
with local immunosuppression, which was partly mediated by the expansion of Tregs. Luminal tumors are in
general poorly infiltrated or are eventually infiltrated with Tregs [62]. However, TN and HER2-positive sub-
types have a pronounced immune infiltration, mostly composed of CD8+ tumor-infiltrating T lymphocytes
(TILs). Whether galectins influence the composition and the quality of the immune infiltration in metastasis
and in breast cancer tumors has been poorly explored. Expression of Gal1 correlated with tumor grade in
human breast cancer particularly in a TN breast cancer model. Silencing tumor-derived Gal1 reduced tumor
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burden and diminished lung metastasis through a mechanism involving neutralization of local and systemic
immunosuppression [54]. Importantly, the frequency of Tregs in the TME, TDLN, spleen, and metastatic lungs
was significantly reduced in Gal1 knockdown tumors. Furthermore, silencing tumor-derived Gal1 induced
down-regulation of the immunoregulatory adaptor LAT in Tregs [54], thus counteracting the immunosuppres-
sive capacity of these cells.
Likewise, Gal3 confers immunosuppression to tumors by modulating T cell signaling and anergy.
Importantly, through its oligomeric structure, Gal3 is able to form lattices that promote distancing of critical
immune receptor molecules, thus modulating signaling thresholds of T cells in the TME. When Gal3 binds to
cytotoxic T cells, it promotes distancing of the TCR from CD8 molecules, thus impairing IFN-γ secretion and
fostering T-cell anergy in TILs. Treatment with LacNac, a disaccharide that dissociates Gal3–glycan interac-
tions, restores TCR-CD8 colocalization and effector function of CD8+ T cells isolated from several sources
including breast carcinoma metastasis, tumor ascites or blood [63]. In addition, Gal3 promotes CD8 T cell dys-
function by acting as a non-canonical ligand of the inhibitory checkpoint LAG-3 in a breast cancer HER-2/neu
transgenic mouse model [64]. Likewise, Gal3 traps the immune checkpoint molecule cytotoxic T lymphocyte
antigen-4 (CTLA-4) on the surface of T cells, thus sustaining inhibitory signals and contributing to disarm
antitumor T-cell responses [65]. In this context, the presence of anti-Gal3 autoantibodies has been reported in
the plasma from patients with metastatic melanoma after partial or complete response to anti-CTLA-4 plus
anti-VEGF mAb therapies, suggesting that Gal3 may potentially have prognostic and predictive value for
immunotherapy response [66]. Interestingly, in immunologically desert tumors, Gal3 binds to glycosylated
IFN-γ and other chemokines in the TME, thus preventing IFN-γ diffusion and avoiding the formation of the
IFN-γ-induced chemokine gradient required for tumor T-cell infiltration [67] (Figure 4).
Like Gal-1, Gal-9 has been defined as a negative regulator of Th1 responses, by selectively deleting TIM-3+
Th1 cells. In fact, systemic Gal9 was associated with Th2 polarization and reduced overall survival in patients
with metastatic melanoma [68]. In vitro, the addition of Gal9 impairs the proliferation of healthy PBMCs,
leading to Th1 cell apoptosis, and promoting Th2 cell phenotypes [68]. In addition, Gal9 enhanced the stability
and function of inducible Tregs by forming a trimolecular complex with CD44 and transforming growth factor
(TGF-β) receptor I (TGF-βRI) that promotes SMAD3 activation. Exogenous Gal9 co-operates with TGF-β1 to
reinforce iTreg cell differentiation and maintenance. In fact, it was demonstrated, that Gal9 acts directly
through the non-coding conserved sequence CNS1 region of the Foxp3 locus, thereby modulating iTreg cell
induction [69]. Interestingly, Gal8, a tandem-repeat type galectin with the ability to recognize α2,3-sialylated
glycans, promotes Treg conversion by activating TGF-β and IL-2R signaling [70].
Neo-angiogenesis and intravasation
Once the tumor cell has detached from the primary site and has invaded and migrated through the peritumoral
surrounding area, it may get into the bloodstream through a process called intravasation. This critical step is
profoundly influenced by the architecture and properties of tumor-associated vessels, both from blood and
lymphatic origin [71]. Tumor-associated vasculature differs substantially from normal vasculature as it is fene-
strated, aberrant and involves weak interactions of adjacent ECs due to the absence of pericyte coverage, which
together with the ability to penetrate endothelial barriers, facilitates the tumor intravasation process. Tumor
angiogenesis refers to the formation of new blood vessels within a tumor, being hypoxia, the major driver of
the angiogenic response. This process is crucial for metastatic spread and is governed by different growth
factors present in the TME including vascular endothelial growth factor (VEGF), epidermal growth factor
(EGF) and FGF, which triggers EC activation. In addition, lymphangiogenesis significantly contributes to the
metastatic cascade, by regulating immune cell influx and tissue fluid homeostasis [71]. Based on these features,
it is not surprising that galectins are also involved in the formation of vascular networks and promotion of
angiogenesis and lymphangiogenesis, thus nourishing tumors and providing novel escape routes.
Expression of Gal-1 is regulated by hypoxia through mechanisms that may depend on either
hypoxia-inducible factor 1α (HIF-1α) or nuclear factor κB (NF-κB activation [72–74]. Importantly, this lectin
reprograms EC biology promoting VEGFR-2 phosphorylation [73,75] and angiogenesis [73,76–78].
Interestingly, hypoxia also remodels the glycan profile of ECs, thus promoting a Gal1 permissive phenotype
which controls paracrine EC signaling. In this context, Gal1 present in the TME, binds to complex N-glycans
on VEGFR2 and promotes neovascularization [73]. Moreover, a decrease in α(2,6)-SA and an increase in
complex branched N-glycan structures, as well as elongation of poly-LacNAc residues facilitate Gal1 binding to
VEGFR2 on ECs, thereby promoting aberrant angiogenesis and conferring resistance to anti-VEGF mAb
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therapy [79] (Figure 5). Furthermore, ECs can take up Gal1 and stimulate their proliferation and migration
through the activation of the H-Ras signaling [80]. Interestingly, in cervical cancer cells, receptor of activated
C-kinase 1 (RACK1) facilitated tumor cell invasion and promoted lymphangiogenesis and LN metastasis
through a mechanism involving Gal1 expression and secretion. Interestingly, this lectin feeds a positive loop
increasing RACK1 levels via activation of the β1 integrin signaling, further reinforcing the pro-metastatic
effect [81].
Figure 5. Extravasation and colonization: Schematic representation of bone marrow and lung metastasis in breast cancer models.
(a) Adhesion and extravasation: (1) Tumor cells may adhere to the endothelium by means of galectin-glycan interactions. Gal1 interacts with cell
surface glycosylated receptors including CD44 or CD326, thus influencing extravasation and cancer cell attachment to the endothelium. Gal3
triggers the exposure of CD44 and E-selectin and promotes adhesion and extravasation through the Thomsen-Friedenreic (TF) antigen. Bone
marrow (BM): (2) Gal3 promotes osteoclast differentiation in the presence of RANKL, triggering Notch and NF-κB signaling. Osteoclasts play key
roles in remodeling the pre-metastatic niche. (3) Gal3 inhibits BM stem cell differentiation and GM-CFS secretion; however, in the presence of late
macrophage precursors it enhances GM-CFS production and macrophage recruitment and polarization. Hematopoietic stem cells can secret
factors such as BMP and TGF-β2 favoring bone remodeling and sustaining dormant phenotypes. Lung: (b) Cells undergoing EMT must turn back
into an epithelial phenotype in order to form macrometastasis. (c) Gal3 promotes the proliferation of tumor cells upon activation of RAS signaling,
favoring a molecular switch from NRAS to KRAS, and the formation of macrometastasis. Also, Gal1 promotes tumor cell proliferation via KRAS
interaction. (d) Since Gal1 may promote Treg cell polarization and increase Treg cell frequency in the lungs, this lectin may contribute to create an
immunosuppressive microenvironment for those DTCs in the lung. In this figure, we represent in colors different tumor cell clones with distinct
tropism (violet-bone marrow/pink and strong grey-lung). Created with BioRender.com.
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Gal1 is far from being the only galectin associated with the angiogenic process. Gal3 is a key player in tumor
vascularization as it stimulates the proangiogenic capacity of tumor-associated macrophages (TAMs) through
mechanisms involving a TGF-β1 and VEGF cross-talk [82]. Moreover, Gal3 also modulates VEGF- and
bFGF-mediated neovascularization through binding to N-glycans on integrin αvβ3 in ECs [83]. Importantly,
Gal3 is also expressed in ECs and interacts with cancer-associated Thomsen–Friedenreic (TF) antigen, a glycan
biomarker exposed in many metastatic human carcinoma cells, [84,85], initiating DTC adhesion to the endo-
thelium [86]. Moreover, in breast and prostate cancer cells, Gal3 also increases adhesion to the endothelium of
well-differentiated microvessels [87]. Furthermore, Gal3 released into the bloodstream of colorectal and melan-
oma cancer patients, promotes hematogenous dissemination via its interaction with TF-expressing MUC1 on
the cancer cell surface [88]. These data suggest that Gal3 not only promotes angiogenesis but may also act as
an endothelium activator affecting the first steps of the DTC intravasation process.
In addition to Gal1 and Gal3, Gal8 also induces migration and morphogenesis of vascular ECs in vitro and
promotes angiogenesis in vivo, in an experimental model of breast cancer. The mechanisms underlying this
effect involve glycosylation-dependent interactions between Gal8 and activated leukocyte cell adhesion molecule
(ALCAM)/CD166) [89].
It has been well-established that certain subpopulations of macrophages significantly contribute to metastasis,
by either promoting angiogenesis or facilitating tumor spreading. Particularly, in breast cancer, the association
of podoplanin-expressing macrophages (PoEMs) with tumor-associated lymphatic vessels correlates with metas-
tasis in LN and in distant organs. In this setting, it has been demonstrated that lymphatic vessels synthesize
Gal8, which in turn promotes adhesion of PoEMs. Once in the lymphatic vessel neighborhood, PoEMs induce
lymphangiogenesis and LN invasion in a glycan-dependent fashion via matrix remodeling, growth factor
release and activation of pro-migratory integrin β1 [90].
Remarkably, alternative splicing has been shown to regulate the length of the linker region between both
CRD of Gal9, affecting its valency and function. This molecular effect is particularly relevant during vascular
development since different Gal9 isoforms selectively control vascularization, exhibiting controversial effects
depending on their concentration and environmental context. The Gal9Δ5 isoform induces in vitro sprouting
and migration of human umbilical vein endothelial cell (HUVEC), but paradoxically, triggers inhibitory effects
on angiogenesis in vivo [91]. In addition, we recently found that adipose tissue-derived Gal12 promotes in vitro
angiogenesis through binding to 30-fucosylated glycans on ECs (Figure 3). Moreover, analysis of in vivo adipose
tissue vasculature showed reduced vascular networks in Gal12-deficient (Lgals12−/−) compared with wild-type
mice, thus emphasizing the role of galectins in the cross-talk between vascular and adipose tissue [92]. Thus,
Gal1, Gal3, Gal8, Gal9, and Gal12 emerge as novel regulators of EC biology and angiogenesis in the TME.
Whether these endogenous galectins selectively control different stages of the vascularization process in a
spatio-temporal manner remains to be elucidated.
Cell plasticity
Metastatic cells have the intrinsic ability to move as individual cells or as a community cluster. The cell migra-
tion process is prevented by E-cadherin junctions that tend to preserve epithelial cells integrity, further counter-
acting cell dissociation or association with other substrates. To overcome this hurdle, tumor cells may hijack
EMT. Interestingly, EMT involves the expression of transcription factors such as Slug, Snail, Twist, ZEB1, and
ZEB2 that orchestrate the transition from an epithelial towards a mesenchymal phenotype, negatively modulat-
ing the expression of E-cadherin, a trademark of epithelial identity. Several galectins have been linked to EMT
programs in several types of cancers. Gal1 induces EMT in human ovarian cancer cells (SKOV3-ip and
SKOV3) via activation of the JNK/p38 signaling pathway [93,94]. Moreover, this lectin also induces EMT in
other tumor types such as hepatocellular carcinoma [95,96], gastric cancer [41,97,98], PDAC, [99], and colon
cancer [100] (Figure 3). Interestingly, Gal3 expression also promotes EMT via a Wnt/β-catenin-dependent acti-
vation in oral tongue squamous cell carcinoma [32] and fosters the expression of EMT-related markers in
colon carcinoma cells [101] (Figure 3). Furthermore, in prostate cancer patients, Gal4-driven EMT was asso-
ciated with poor survival [102]. Interestingly, evidence from experimental models and clinical data indicates
that EMT programs share characteristics with stemness programs. Cancer stem cells (CSCs), stem-like cells
within tumors, have been proposed to play central roles in the metastatic process by virtue of their self-renewal
capacity and resistance to different anticancer treatments including chemotherapy. For example, in breast
cancer cells, EMT induction drives the generation of cells with stem-like properties characterized by a
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CD44high/CD24low surface phenotype [103]. Additionally, in numerous tumor types, including several forms of
brain cancer, prostate cancer, colon cancer, lung cancer, hepatocellular carcinoma, and ovarian cancer, the
marker CD133 has been proposed to identify a cell population with CSC properties [104]. In this context, Gal1
plays a pivotal role in tumorigenesis and invasiveness of CD133+ CSCs in lung adenocarcinoma [105]. Even
more, Gal3 promotes lung cancer stemness properties by activating the EGFR/c-Myc/Sox2 axis [106] and the
αvβ3 integrin/KRAS/NFkB pathway [107]. Gal3 also supports stemness in A2780 and OVCAR3 ovarian cancer
cells by activating the intracellular domain of Notch1 [108]. Finally, it was proposed that the association of
Gal9 and TIM-3 expressed on the surface of leukemic stem cells, activates both NF-κB and β-catenin pathways,
promoting stemness and self-renewal in human acute myeloid leukemia (AML) [109]. Thus, galectins have a
broad impact in the control of cell plasticity, an essential feature that shapes migratory, invasive and metastatic
properties of tumor cells through activation of EMT and stem cell programs.
Colonization
Survival in the circulation and extravasation
Once the tumor cell penetrates the basement membrane, it gets into the blood or lymphatic vessels and tra-
verses through the bloodstream until reaching the colonization site. During this journey, circulating tumor cells
(CTCs) need to overcome the unfavorable conditions of the bloodstream and survive. For that purpose, tumor
cells form clusters, which protect them from the shear forces and allow their survival in the circulation until
they reach a distant organ for seeding.
The maintenance of cancer cell clusters is dependent on the ability of tumor cells to form heterotypic and
homotypic adhesive interactions, that are critical for the establishment of secondary lesions in distant tissues
[110,111]. Several studies showed that Gal1 promotes both homotypic and heterotypic aggregation of tumor
cells [112,113] by cross-linking several glycosylated ligands presents on the tumor cell surface as well as in
ECM glycoproteins including laminin and fibronectin [26] (Figure 3). Gal1 mediates homotypic cell aggrega-
tion in melanoma cells by interacting with the glycoprotein 90K/Mac-2BP (a Gal3-binding protein) [113]. In
addition, Gal1 interacts with adhesion molecules such as CD44 or CD326 affecting extravasation and cancer
cell attachment to the endothelium in breast cancer [114].
Interestingly, Gal3 in its pentameric form, binds to core 1 antigen (TF; Galβ1,3GalNAcα-1-0-Ser/Thr) and
induces heterotypic and homotypic aggregation. Elevated levels of Gal3 in cancer patient’s plasma augmented
cancer cell adhesion to ECs under both static and flow conditions, further increasing transendothelial invasion.
The interaction of Gal3 with the TF antigen present in ECs permits the polarization of cancer-associated
MUC1 protein and exposes surface adhesion molecules such as CD44 and E-selectin, thus enhancing cancer-
endothelium adhesion in colorectal and melanoma cancer cells [88]. Interaction between Gal3 and MUC1 pro-
motes emboli formation and survival in the circulation of colon and breast cancer CTCs, leading to profound
consequences in metastasis formation [115]. In addition, serum levels of Gal2, Gal4, and Gal8 significantly
increased in plasma from patients with metastasis, enhancing the interactions between the CE and the TF
disaccharide present on cancer-associated MUC1 [116].
As mentioned above, the role that Gal9 plays in metastasis is less clear and even controversial. Evidence indi-
cates that certain Gal9 isoforms may promote cell adhesion and cluster formation, while others inhibit these
pro-metastatic processes. Whereas Gal9L (or gal-9FL) isoform decreases E-selectin expression, Gal9M (or
gal-9Δ5) and S (or gal-9Δ5/6) increase E-selectin levels in LoVo colon carcinoma cells. Overexpression of these
three isoforms in LoVo cells increased attachment to ECM proteins, while Gal9M and S overexpression fosters
adhesion to HUVEC in vitro [117]. Furthermore, in luminal breast cancer cells (MCF7 cell line) Gal9 induced
cluster formation, while Gal9M and S variants inhibited the adhesion to collagen, fibronectin, vitronectin and
laminin [118]. Moreover, in OSCCs, Gal9 increased adhesion to laminin and fibronectin [119] (Figure 3).
As mentioned above, platelets may influence the metastatic potential of CTC by contributing to clog forma-
tion and/or increasing the adhesion to the endothelium and transmigration via P-selectin [120]. Through the
formation of heterotypic aggregates, platelets may protect tumor cells against immune attack and circulation
shear forces [120], while secreting pro-inflammatory mediators that sustain tumor growth and stroma forma-
tion [121]. A growing body of experimental evidence indicates that Gal1 controls platelet homeostasis with
potential implications in metastasis. Gal1 induces platelet and leukocyte aggregation in a carbohydrate-
dependent manner, synergizing with ADP or thrombin to form platelet clusters and ATP release. At the
molecular level, Gal1 induces conformational changes in the integrin complex GPIIb/IIIa, a pre-requisite for
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platelet cross-linking, and favor conformational changes in platelets, including F-actin polymerization and
lamellipodia as well as filopodia extension [122]. Also, Gal8 promotes the transition of αIIbβ3 integrin towards
an activate state favoring platelet aggregation and clustering [122,123]. Mechanistically, both lectins promote
thromboxane generation, P-selectin expression, and granule secretion that favors the aggregation phenomenon
[123,124]. Thus, by interacting with glycosylated ligands present on ECs or platelets, galectins mediate clog for-
mation and platelet-induced metastasis. Once CTCs have surmounted the challenge of moving through the cir-
culatory tract and have already extravasated, they are prepared to colonize the pre-metastatic niche, further
generating dormant or active metastasis.
Colonization of the pre-metastatic niche
Once the vasculature is left behind, the tumor cell needs to adapt to the new microenvironment in order to col-
onize and form metastasis. DTCs establish the pre-metastatic niche through a complex cross-talk between the
primary tumor and stromal cells, by secreting growth factors and chemokines that systemically stimulate the
bone marrow (BM) to produce ‘pro-niche’ molecules. For example, breast cancer DTCs secrete IL-11 and
express Jagged1, which modulate osteoclast function, thus favoring bone metastasis through the release of sur-
vival factors from the bone matrix. However, the survival of the DTCs in the pre-metastatic niche does not
guarantee the formation of large macroscopic metastasis. In fact, DTCs that reach the metastatic organ can
remain in a dormant state for years and even decades. For example, in BM, hematopoietic stem cells (HSCs)
secrete pro-dormancy factors such as GAS6, BMP4, BMP7, and TGF-β2 [11]. As galectins play important roles
in shaping stroma–tumor cell interactions, it is likely that they could influence the establishment of a pre-
metastatic niche. In fact, Gal3 restructures the BM microenvironment which in turn regulates its cleavage status
during osteoclastogenesis. At a mechanistic level, intact Gal3 interacts with myosin-2A enhancing osteoclasto-
genesis in the presence of RANKL, while its cleavage suppresses osteoblast differentiation via Notch signaling,
thus contributing to pro-metastatic osteolysis in breast and prostate cancer [125–128]. Gal3 also affects the dif-
ferentiation of BM-derived precursors [129], thus influencing commitment toward osteoclast, osteoblast,
lymphoid and myeloid cell compartments and enhancing colonization and metastasis in breast and prostate
cancer (Figure 5).
A dormant cell may remain in a latent state in the target organ for years. However, a perturbation in the
homeostatic state of the environmental conditions may occur, inducing awakeness of dormant cells. Signals
may arise from inside the cells and may include activation of proliferative signals or may involve the release
of inhibitory brakes that control cell cycle progression. Both Gal1 and Gal3 can interact with oncogenic RAS
proteins, inducing RAS membrane anchorage and activation, opening the gates towards proliferation and
macrometastasis [130,131]. Moreover, Gal1 promotes tumor cell proliferation through activation of ERK1/2
upon Ras activation in lung cancer models [132]. Also, Gal3 activates KRAS, promoting a molecular switch
from NRAS to KRAS in breast cancer patients [133] (Figure 5). Although further studies are awaited, these
growing body of experimental evidence, even when they are indirect, may suggest a potential role of galectins
in dormancy.
The roles of galectins in modulating EMT and stemness, in regulating metalloproteases that remodel the
microenvironment, in generating local and systemic immunosuppression and in inducing angiogenesis have
been discussed here. Altogether, these reports suggest that galectin–glycan interactions may have a broad
impact in the colonization of the metastatic organ and will largely contribute to the metastatic burden.
Galectin-targeted strategies
As galectins modulate different Hallmarks of Metastasis, targeting galectin–glycan interactions may represent a
promising therapeutic strategy to treat or reprogram metastatic disease. Several inhibitors have been developed,
including small-molecule inhibitors, multivalent saccharide ligands, antagonistic peptides, and blocking anti-
bodies and some of them are currently under evaluation in clinical trials.
Carbohydrate-derived small-molecule inhibitors
This approach is mainly based on the use of chemically modified natural galectin ligands, such as the disac-
charides lactose (Lac) or N-acetyllactosamine (LacNAc) to target the CRD of galectins. As the development
of these inhibitors involves a full understanding of the biochemistry of galectin–glycan interactions, efforts
are being made to generate galectin inhibitors that target individual members of the family with higher affin-
ity and selectivity (particularly Gal1, Gal3, and Gal7). The disadvantages of these inhibitors for use in clinical
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Table 1. Clinical trials that target galectins and their respective ligands (Adaptation from 156) Part 1 of 2
Sponsor Compound
Proposed
target Origin Indication Phase Title of the study NTC Number Status
La Jolla
pharmaceuticals
GSC-100 Gal3 Plant-based Chronic kidney
disease
1 Safety study of
GCS-100 to treat
chronic kidney disease
NCT01717248 Completed (n = 29)
Chronic kidney
disease













NCT00514696 Completed (n = 24)
Multiple
myeloma
1 Safety and efficacy study
of GCS-100LE in the
treatment of multiple
myeloma


























NCT00054977 Completed (n = 40)
Melanoma 2 Peptide vaccinations
plus GM-CT-01 in
melanoma
NCT01723813 Terminated (due to














2 Study to test the benefit
and safety of GM-CT-01
in combination with
5-FU to treat bile duct
and gall bladder cancer


































NCT01899859 Completed (n = 31)
Continued
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settings include low in vivo bioavailability, susceptibility to glycosidase hydrolysis, and fast clearance.
Although many alternatives have emerged over the years, the poor selectivity still remains a hurdle for this
approach [14,134].
Thiodigalactoside (TDG), a non-selective inhibitor of Gal1, is an alternative disaccharide to overcome the
poor bioavailability of lactose derivatives. Ito and colleagues observed that following TDG administration,
tumor progression and metastasis in murine models of breast and colon adenocarcinoma decreased.
Interestingly, TDG prevents binding of Gal1 to CD44 and CD326 receptors on the surface of CSCs
[114,135,136]. Symmetrical modifications of TDG at O3 and O30 positions increased galectin-binding affinities
providing the potent small-molecule inhibitors of Gal3 [137]. This includes the C2-symmetric TD139 (from
Galecto Biotech) or its asymmetrical derivative TAZTDG [138]. Phase Ib/IIa clinical trials of TD139 as a dry
powder for inhalation revealed early promising results in patients with idiopathic pulmonary fibrosis (Table 1).
Further studies should be conducted to generate more selective and potent small-molecules inhibitors targeting
individual galectins.
Table 1. Clinical trials that target galectins and their respective ligands (Adaptation from 156) Part 2 of 2
Sponsor Compound
Proposed








cell lung cancer, and
squamous cell head and
neck cancer patients
NCT02575404 Recruiting (n = 22)




2 Clinical trial to evaluate
efficacy of GR-MD-02
for treatment of liver
fibrosis in patients with
NASH with advanced
fibrosis (NASH-FX)
NCT02421094 Completed (n = 30)
Psoriasis 2 An open-label, phase 2a















3 Galectin-3 blockade in
patients with high blood
pressure
NCT01960946 Active, not
recruiting (n = 59)
EcoNugenics PectaSol-C Gal3 Plant-based Prostatic
neoplasms
3 Effect of modified citrus
pectin on PSA kinetics
in biochemical relapsed
PC with serial increases
in PSA
NCT01681823 Completed (n = 60)






control trial) of TD139 vs
placebo in HV’s (human
volunteers) and IPF
patients
NCT02257177 Completed (n = 60)




1 A phase I, first-in-man
study of OTX008 given
subcutaneously as a
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Carbohydrate-derived polysaccharide inhibitors
Natural polysaccharides have emerged as high-affinity galectin inhibitors. Modified citrus pectin (MCP) and
Davanat (GM-CT-01) are the best-studied galectin inhibitors derived from natural sources. Pectins are a family
of complex polysaccharides, which are found in high amounts in the plant primary cell wall [134]. MCP, a
soluble, orally ingested dietary carbohydrate fiber, has been shown to inhibit Gal3 function and suppress tumor
growth in vivo [134,139,140]. Different commercial forms of MCP have been incorporated into clinical trials.
Among these compounds, Pectasol and its most recent version Pectasol-C (EcoNugenics), GCS-100, and
GBC-590 (Safescience) can be mentioned. GM-CT-01 (DAVANAT) is a β-D-(1→ 4)-galactomannan-based
compounds isolated from the seeds of Cyamopsis tetragonoloba (Guar gum). At present, there is an ongoing
phase II clinical trial using a GM-CT-01 vaccine in patients undergoing diffuse melanoma. GR-MD-02 is a
pectin-derived galactoarabino-rhamnogalacturonan polysaccharide and a modified version of DAVANAT® [141].
Both DAVANAT and GR-MD-02 display comparable inhibition of Gal1 and Gal3. There is early encouraging
data from a phase 1b clinical trial of GR-MD-02 (Galectin Therapeutics) in combination with the anti-PD-1
mAb Pembrolizumab, (Merck) demonstrating its effectiveness against advanced melanoma with 5 of 8 respon-
ders (2 complete responders and 3 partial responders). In addition, a clinical trial of GR-MD-O2 in combination
with the anti-CTLA-4 mAb Ipilimumab for metastatic melanoma treatment is currently active. However, in spite
of considerable progress, more work remains to be done to link the therapeutic activity of these compounds
with mechanistic determinants of galectin binding and function.
Peptide-derived inhibitors
This strategy is based on the use of peptides or peptidomimetics to target galectins at their CRD or/at distant
sites. G3-C12 is an oligopeptide (ANTPCGPYTHDCPVKR) that binds Gal3 CRD (Kd = 72 nM) [142]. This
peptide prevented the metastasis of breast cancer cells to the lung in mouse models. Despite the need of struc-
tural studies describing Gal-3/G3-C12 peptide interaction, preliminary results showed encouraging data to be
used as a proof-of-evidence to target Gal3-overexpressing cancers such as melanoma [143]. Anginex is an anti-
angiogenic synthetic peptide that binds to the β-sheet configuration of Gal1 [144]. Anginex binds to Gal1 and
inhibits neoplastic proliferation, migration, and angiogenesis, thereby inhibiting tumor growth [76]. Anginex
prevents Gal1 uptake by ECs preventing translocation of H-Ras-GTP and signaling via the Raf/MEK/ERK
kinase cascade. Anginex may also recognize other galectins such as Gal2, 7, 8 (N-terminal), and 9
(N-terminal), although with lower affinities [145]. The results of several clinical studies using anginex in com-
bination with radiotherapy and/or chemotherapy showed that this peptide sensitizes tumor-associated ECs to
radiotherapy, thus enhancing clinical success [146,147]. OTX008 is a caliraxene-based compound and a non-
peptidic mimetic of anginex. It down-regulates cancer cell proliferation, invasion, and tumor angiogenesis in a
variety of tumor cells [148] and has undergone a phase I clinical trial administered subcutaneously to patients
with advanced solid tumors (Table 1) [149]. Further studies are awaited to design more selective peptide inhibi-
tors targeting individual galectins and to elucidate the effect of glycosylated ligands on its effects.
Neutralizing antibodies
To develop galectin inhibitors, an important obstacle to overcome is the high similarity in the CRD structures
among different members of the galectin family. The differential activities of individual galectins in normal and
pathological processes [150,151] explain the urgent need of developing potent and selective inhibitors such as
blocking antibodies. A neutralizing anti-Gal1 (F8.G7) mAb inhibited tumor growth and angiogenesis in mice
with Kaposi’s sarcoma by targeting Gal1 binding to VEGFR2 and its subsequent phosphorylation [73,79].
Recently, a novel anti-human Gal1 mAb (Gal1-MAb3) with both angioregulatory and immunostimulatory cap-
acities has been developed [152]. Interestingly, several trials are currently recruiting patients to evaluate the effi-
cacy of blocking antibodies against TIM-3, a glycosylated receptor recognized by Gal9, for the treatment of
advanced solid tumors and hematologic malignancies (NCT02817633, Eli Lilly and Co. and NCT03066648
Novartis).
Small interfering RNA (siRNA) and aptamers
Small interfering RNA (siRNA) has also been proposed as an alternative approach for galectin inhibition. Park
et al. demonstrated that siRNA-mediated silencing of Gal3 in a human osteosarcoma cell line resulted in
decreased tumor cell migration and invasiveness [153]. Interestingly, these nucleic acid-based antagonists have
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become an alternative approach to overcome drug delivery through the blood–brain barrier. Van Woensel et al.
used Gal1 siRNA (siGal1) loaded on a chitosan nanoparticle delivered intranasally to mice in an experimental
model of glioblastoma multiforme. The siGal1 administration reduced Gal1 expression in the TME, inhibited
tumor cell proliferation and migration, and increased CD5+ B cell- and CD8+ T-cell activation [154]. More
recently, in vivo delivery of a Gal1-specific aptamer showed promising results suppressing tumor growth in vivo
and restoring T cell-mediated immunity by blocking interactions between Gal1 and CD45 [155]. A better
understanding and definition of the therapeutic window of application of these treatments during early dissem-
ination and dormancy will be crucial for better therapy design. Moreover, combination with current therapies,
such as immunotherapies, may enhance therapeutic outcomes and increase overall survival and progression-free
survival in a larger number of patients.
Conclusions and future perspectives
Galectins have emerged as master regulators of the metastatic cascade providing tumor cells with a wide range
of abilities considered to be ‘Hallmarks of Metastasis’. By co-opting or subverting physiologic cellular circuits,
galectins hierarchically shape the dissemination of malignant cells, rising as novel biomarkers and therapeutic
targets. Particularly, a molecular signature, dominated by Gal1, Gal3 and Gal9, is associated with poor progno-
sis in many cancer types and directly or indirectly linked to modulation of early or late metastatic events.
Targeting of galectins or their specific glycosylated ligands either alone or in combination with current therap-
ies (chemotherapy, immunotherapies, anti-angiogenic therapy, targeted therapies, radiotherapy) [156,157] may
represent the sleeping-beauty of the next generation of anticancer treatments. Notwithstanding several research
groups are developing galectins inhibitors, it is still unclear whether the intra- or extracellular activities should
be targeted in order to restrain tumor progression. Future studies should be focused on elucidating the role of
galectins in early dissemination and dormancy programs to more precisely establish the therapeutic window
required for better clinical responses. By adjusting spatio-temporal variables, dissecting their precise roles in the
metastatic cascade, and designing more selective and rational inhibitors, anti-galectin therapy is becoming a
novel and promising therapeutic approach for treating metastatic disease in several human cancers.
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